Mangoceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Mangoceuticals, Inc. (MGRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.45 per share for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Mangoceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $5.55.
- Mangoceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $5.55, a 8.26% decline from fiscal 2023.
- Mangoceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $6.05, a 450.00% increase from fiscal 2022.
- Mangoceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.10.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.45 10-Q · filed 2026-08-13 | $2.30 10-K · filed 2026-04-01 | ||||
| 2025-09-30 | $2.30 10-Q · filed 2025-11-14 | |||||
| 2025-06-30 | $5.55 10-Q/A · filed 2025-11-14 | |||||
| 2025-03-31 | $5.55 10-Q · filed 2025-05-15 | |||||
| 2024-12-31 | $5.55 10-K · filed 2026-04-01 | |||||
| 2024-09-30 | $5.55 10-Q · filed 2024-11-14 | |||||
| 2023-12-31 | $6.05 10-K · filed 2025-03-20 | $0.40 10-K · filed 2024-04-01 | ||||
| 2023-09-30 | $16.50 10-Q · filed 2024-11-14 | $1.10 10-Q · filed 2023-10-27 | ||||
| 2023-06-30 | $1.10 10-Q · filed 2023-07-28 | |||||
| 2022-12-31 | $1.10 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |